rmi 12330a has been researched along with calcimycin in 1 studies
| Studies (rmi 12330a) | Trials (rmi 12330a) | Recent Studies (post-2010) (rmi 12330a) | Studies (calcimycin) | Trials (calcimycin) | Recent Studies (post-2010) (calcimycin) |
|---|---|---|---|---|---|
| 141 | 0 | 24 | 11,946 | 40 | 444 |
| Protein | Taxonomy | rmi 12330a (IC50) | calcimycin (IC50) |
|---|---|---|---|
| XBP1 | Homo sapiens (human) | 1.41 | |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, MM; Lee, EK; Lin, HR; Wong, AO; Xiao, D | 1 |
1 other study(ies) available for rmi 12330a and calcimycin
| Article | Year |
|---|---|
Regulation of growth hormone release in common carp pituitary cells by pituitary adenylate cyclase-activating polypeptide: signal transduction involves cAMP- and calcium-dependent mechanisms.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Calcimycin; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Carps; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Activators; Enzyme Inhibitors; Growth Hormone; Imines; In Vitro Techniques; Ionophores; Isoquinolines; Neuropeptides; Neurotransmitter Agents; Nifedipine; Phosphodiesterase Inhibitors; Pituitary Adenylate Cyclase-Activating Polypeptide; Pituitary Gland; Signal Transduction; Sulfonamides; Vasoactive Intestinal Peptide | 2002 |